ES2177581T3 - Uso de compuestos de piperidina en el tratamiento de esquizofrenia. - Google Patents

Uso de compuestos de piperidina en el tratamiento de esquizofrenia.

Info

Publication number
ES2177581T3
ES2177581T3 ES94924708T ES94924708T ES2177581T3 ES 2177581 T3 ES2177581 T3 ES 2177581T3 ES 94924708 T ES94924708 T ES 94924708T ES 94924708 T ES94924708 T ES 94924708T ES 2177581 T3 ES2177581 T3 ES 2177581T3
Authority
ES
Spain
Prior art keywords
schizophrenia
treatment
piperidine compounds
mammal
sulphur
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94924708T
Other languages
English (en)
Inventor
Franklin Porter Bymaster
Harlan E Shannon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Application granted granted Critical
Publication of ES2177581T3 publication Critical patent/ES2177581T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

LA PRESENTE INVENCION SE REFIERE A UN NUEVO METODO PARA TRATAR A UN MAMIFERO QUE SUFRA O SEA SUSCEPTIBLE A LA ESQUIZOFRENIA Y A ENFERMEDADES DE FORMA ESQUIZOFRENICA QUE COMPRENDE LA ADMINISTRACION A DICHO MAMIFERO DE UNA CANTIDAD EFECTIVA DE UN COMPUESTO DE LA FORMULA (I), EN LA QUE Z1 ES OXIGENO O AZUFRE.
ES94924708T 1993-08-19 1994-08-15 Uso de compuestos de piperidina en el tratamiento de esquizofrenia. Expired - Lifetime ES2177581T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10930093A 1993-08-19 1993-08-19

Publications (1)

Publication Number Publication Date
ES2177581T3 true ES2177581T3 (es) 2002-12-16

Family

ID=22326932

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94924708T Expired - Lifetime ES2177581T3 (es) 1993-08-19 1994-08-15 Uso de compuestos de piperidina en el tratamiento de esquizofrenia.

Country Status (23)

Country Link
EP (1) EP0734259B1 (es)
JP (1) JP3126736B2 (es)
KR (1) KR100360575B1 (es)
CN (1) CN1087936C (es)
AT (1) ATE218864T1 (es)
AU (1) AU701292B2 (es)
CA (1) CA2169839C (es)
CZ (1) CZ285030B6 (es)
DE (1) DE69430816T2 (es)
DK (1) DK0734259T3 (es)
ES (1) ES2177581T3 (es)
FI (2) FI960747A (es)
HU (1) HU221729B1 (es)
IL (1) IL110708A (es)
NO (1) NO312706B1 (es)
NZ (2) NZ336597A (es)
PT (1) PT734259E (es)
RU (1) RU2191580C2 (es)
SG (1) SG55071A1 (es)
TW (1) TW442284B (es)
UA (1) UA63876C2 (es)
WO (1) WO1995005174A1 (es)
ZA (1) ZA946324B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998404A (en) * 1994-10-24 1999-12-07 Eli Lilly And Company Heterocyclic compounds and their use
US5821371A (en) * 1994-10-24 1998-10-13 Eli Lilly And Comany Heterocyclic compounds and their preparation and use
US5605908A (en) * 1994-10-24 1997-02-25 Eli Lilly And Company Heterocyclic compounds and their use
US5726193A (en) * 1994-10-31 1998-03-10 Eli Lilly And Company Method for treating anxiety
US5574028A (en) * 1994-10-31 1996-11-12 Eli Lilly And Company Method for treating anxiety
US5488056A (en) * 1994-10-31 1996-01-30 Eli Lilly And Company Method for treating anxiety
PT709094E (pt) * 1994-10-31 2000-08-31 Lilly Co Eli Metodo para o tratamento da ansiedade
US5565475A (en) * 1994-11-08 1996-10-15 Muhlhauser; Mark A. Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives
US5852037A (en) * 1995-11-13 1998-12-22 Eli Lilly And Company Method for treating anxiety
US5763457A (en) * 1995-11-13 1998-06-09 Eli Lilly And Company Method for treating anxiety
EP0821956A1 (en) * 1996-08-01 1998-02-04 Eli Lilly And Company Method for treating disruptive behavior disorders
US6043258A (en) * 1996-08-01 2000-03-28 Eli Lilly And Company Method for treating disruptive behavior disorders with xanomeline
EP0821957A3 (en) * 1996-08-01 1998-04-22 Eli Lilly And Company Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating substance abuse
EP0821959A3 (en) * 1996-08-01 1998-09-16 Eli Lilly And Company Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine for treating nicotine withdrawal
US6117890A (en) * 1996-08-01 2000-09-12 Eli Lilly And Company Method for treating bipolar disorder
EP0821954A1 (en) * 1996-08-01 1998-02-04 Eli Lilly And Company Method for treating mental retardation
US6090829A (en) * 1996-08-01 2000-07-18 Eli Lilly And Company Method for treating excessive aggression
EP0821958A3 (en) * 1996-08-01 1998-07-08 Eli Lilly And Company Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating excessive aggression
PT821955E (pt) * 1996-08-01 2002-07-31 Lilly Co Eli Uso de 3-(4-hexiloxi-1,2,5-tiadiazol-3-il)-1,2,5,6-tetrahidro-1-metilpiridina (xanomelina) para o tratamento da doenca bipolar
DE69825605T2 (de) 1997-05-29 2005-09-15 H. Lundbeck A/S Behandlung der schizophrenie und der psychose
US6034108A (en) * 1997-07-28 2000-03-07 Eli Lilly And Company Method for treating mental retardation
PL3061821T3 (pl) 2009-07-22 2020-01-31 PureTech Health LLC Kompozycje do leczenia zaburzeń łagodzonych przez aktywację receptora muskarynowego
EA202190356A1 (ru) 2018-09-28 2021-08-13 Каруна Терапеутикс, Инк. Композиции и способы лечения расстройств, ослабляемых активацией мускариновых рецепторов
WO2021097427A1 (en) 2019-11-15 2021-05-20 Karuna Therapeutics, Inc. Xanomeline derivatives and methods for treating neurological disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ225999A (en) * 1987-09-10 1992-04-28 Merck Sharp & Dohme Azacyclic- or azabicyclic-substituted thiadiazole derivatives and pharmaceutical compositions
US5043345A (en) * 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
DK198490D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
DK198390D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse

Also Published As

Publication number Publication date
EP0734259B1 (en) 2002-06-12
FI960747A0 (fi) 1996-02-19
AU7490294A (en) 1995-03-14
DK0734259T3 (da) 2002-09-30
HU9600364D0 (en) 1996-04-29
DE69430816T2 (de) 2002-12-19
CA2169839C (en) 2002-06-11
HUT75111A (en) 1997-04-28
EP0734259A1 (en) 1996-10-02
AU701292B2 (en) 1999-01-21
HU221729B1 (hu) 2002-12-28
FI960747A (fi) 1996-04-17
NO960619L (no) 1996-04-18
CN1133008A (zh) 1996-10-09
SG55071A1 (en) 1998-12-21
IL110708A0 (en) 1994-11-11
WO1995005174A1 (en) 1995-02-23
NZ271311A (en) 1999-09-29
TW442284B (en) 2001-06-23
KR100360575B1 (ko) 2003-03-10
JPH09501658A (ja) 1997-02-18
FI20050461A (fi) 2005-04-29
ATE218864T1 (de) 2002-06-15
DE69430816D1 (de) 2002-07-18
CA2169839A1 (en) 1995-02-23
RU2191580C2 (ru) 2002-10-27
NO312706B1 (no) 2002-06-24
CN1087936C (zh) 2002-07-24
UA63876C2 (en) 2004-02-16
KR960703592A (ko) 1996-08-31
ZA946324B (en) 1996-02-19
JP3126736B2 (ja) 2001-01-22
IL110708A (en) 1998-12-06
CZ42696A3 (en) 1996-11-13
PT734259E (pt) 2002-11-29
NO960619D0 (no) 1996-02-16
CZ285030B6 (cs) 1999-05-12
NZ336597A (en) 2001-02-23

Similar Documents

Publication Publication Date Title
ES2177581T3 (es) Uso de compuestos de piperidina en el tratamiento de esquizofrenia.
DE69523350D1 (de) Behandlung von hyperproliferativen Gefässerkrankungen
EP0613883A4 (en) HYDROXAMIC ACID DERIVATIVE.
ATE417836T1 (de) Verfahren und intermediate zur herstellung von retroviralen proteasehemmern
EP0604641A4 (en) COMPOSITION CONTAINING AMINO DERIVATIVES OR RELATED TO BENZOIC ACID AMINES AND USES THEREOF, INCLUDING IN THE TREATMENT OF INFLAMMATORY DISEASES.
ES2106531T3 (es) Compuestos de dibenzoxazepina substituidos en 2, 3, 4, 5, 6, 7, 8, 9 y/o 10, composiciones farmaceuticas y metodos de uso.
ATE224372T1 (de) Substituierte 6-alkylphenanthridine
ATE180669T1 (de) Verwendung von pregnanderivaten zur behandlung von tumoren
ATE169217T1 (de) Verwendung von furanonderivaten zur vorbeugung oder behandlung von autoimmunkrankheiten
MX9803901A (es) Compuestos de di-terbutilfenol que contienen azufre utiles como agentes anti-inflamatorios.
MX9606494A (es) Compuestos organicos.
KR880007070A (ko) 백내장 치료용 약학 조성물
NO20003481L (no) FremgangsmÕte for behandling av COPD
DE68921051D1 (de) Pyridin-3-percarboxylsäure monopersulfat.
DE59504374D1 (de) Verwendung von Deoxyspergualin zur Herstellung eines Arzneimittels zur Behandlung von entzündlich-hyperreaktiven Erkrankungen